Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

capital markets and the potential difficulties we might face in raising additional capital. Market prices and market demand for securities in biotechnology companies are volatile and there are no assurances that we will have the ability to raise funds when required.

Capital Expenditures

We spent $257,304 on intellectual property in the first quarter of 2008 compared to $218,177 in the first quarter of 2007. The change in intellectual property expenditures reflects the timing of filing costs associated with our expanded patent base. As well, we have benefited from fluctuations in the Canadian dollar as our patent costs are typically incurred in U.S. currency. At the end of the first quarter of 2008, we had been issued over 170 patents including 26 U.S. and eight Canadian patents as well as issuances in other jurisdictions. We also have over 180 patent applications filed in the U.S., Canada and other jurisdictions.

Investing Activities

Under our Investment Policy, we are permitted to invest in short-term instruments with a rating no less than R-1 (DBRS) with terms less than two years. We have $14,635,920 invested under this policy and we are currently earning interest at an effective rate of 2.74% (2007 - 4.08%).

CHANGES IN ACCOUNTING POLICIES INCLUDING INITIAL ADOPTION

Capital Disclosures

On January 1, 2008, the Company adopted the new recommendations of the Canadian Institute of Chartered Accountants ("CICA") for disclosure of the Company's objectives, policies and processes for managing capital (CICA Handbook Section 1535), as discussed further in Note 5 of our interim consolidated financial statements.

Financial Instruments - Disclosures

On January 1, 2008, the Company adopted the new recommendations of the CICA for disclosures about financial instruments, including disclosures about fair value and the credit, liquidity and market risks associated with financial instruments (CICA Handbook Section
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015  "Everybody is affected by cancer sooner ... is frankly brutal. We,ve got to get away from ... or witnessed a loved one or friend battling for ... devastation chemotherapy and other treatments cause the human body. ... give up and succumb to the disease. Dr. Dionne ...
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of ... results for the fourth quarter and full year ended ... Highlights(Compared to the fourth quarter 2013) , Quarterly ... from $22.9 million in the prior year period. Excluding ... vaccine of $0.1 million in the fourth quarter of ...
(Date:4/20/2015)... April 20, 2015 Whitehouse Laboratories is ... undergone its most recent Food and Drug Administration (FDA) ... issued. The five day, GMP compliance inspection, as based ... 31st through April 6th and was granted NAI ... areas of the strict Good Manufacturing Practice (GMP) quality ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Reed ... leader in regulatory data management, preparation, and submission to ... the availability of a new Lot Distribution Report (LDR) ... required to remain compliant with the FDA’s new rule ... the FDA to monitor the volume and timing of ...
Breaking Biology Technology:Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3
... SAN DIEGO, Jan. 6, 2012  AnaptysBio, Inc., ... the initiation of new strategic alliances with ... pharmaceutical company.    The strategic alliance announced today ... the Swiss-based pharmaceutical company and follows an ...
... Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular ... definitive agreement to acquire MultiGEN Diagnostics, Inc.,s (,MultiGEN,) clinical ... shares of common stock of TrovaGene, with an additional ... common stock, subject to the achievement of specific sales ...
... This press release is available in Spanish . ... San Sebastian and Japan, a relay reaction of hydrogen atoms ... way of manipulating matter could open up new ways to ... Thomas Frederiksen, presently working in the Donostia International Physics Center ...
Cached Biology Technology:AnaptysBio Announces New Strategic Antibody Discovery 2AnaptysBio Announces New Strategic Antibody Discovery 3TrovaGene Acquires CLIA - Certified Laboratory 2TrovaGene Acquires CLIA - Certified Laboratory 3Relay race with single atoms: New ways of manipulating matter 2
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... -- FirstMark, the diagnostic division of GenWay ... company will be exhibiting at the inaugural Atlanta ... of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory ... provide a new, needs-based and convenient forum for ...
... Center of NYU School of Medicine will hold its ... honor three outstanding leaders in biomedical research. The Dart/NYU ... in the development of pharmaceuticals and honors those scientists ... care provided at the patient,s bedside. Recipients of this ...
... VIEW, CA (April 6, 2012) Using its ... company, has found five significant genetic associations for hypothyroidism ... conducted to date. The details of the study are ... . "With nearly 90 percent of our 125,000 ...
Cached Biology News:FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 3NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 4NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 523andMe identifies 5 significant genetic associations for hypothyroidism 2
Fingerprinting II cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to the Fingerp...
Fingerprinting II comparative quantification and polymorphism analysis is an optional module that adds comparative quantification and polymorphism analysis functions to the Fingerprinting II Basic so...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... The new Pierce ready-to-use 2-D gel marker mix ... This 2-D gel marker mix contains a complement ... important features of value to those who use ... pI and molecular weight values of proteins undergoing ...
Biology Products: